What is the 13F Pro Quality Score for QNCX?

13F Pro ranks Quince Therapeutics, Inc. (QNCX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View QNCX's current score at https://13fpro.ai/company/QNCX (free sign-up required for the full ranking).

Where does 13F Pro source QNCX data?

All Quince Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Quince Therapeutics, Inc. files with the SEC under CIK 1662774. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is QNCX in?

Quince Therapeutics, Inc. (QNCX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is QNCX research updated on 13F Pro?

QNCX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Quince Therapeutics, Inc.(QNCX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1662774 QNCX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

QNCX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Quince Therapeutics, Inc. (QNCX), a Healthcare sector company. QNCX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Quince Therapeutics, Inc. reports net income of $-75.5M, free cash flow of $-18.9M. Top institutional holders of QNCX by reported 13-F value include BALYASNY ASSET MANAGEMENT L.P., TUDOR INVESTMENT ET AL, TUDOR INVESTMENT ET AL, based on the most recent SEC filings. QNCX trades on the Nasdaq exchange and files with the SEC under CIK 1662774. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QNCX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Quince Therapeutics, Inc. directly from SEC EDGAR.

✦

Fun facts about Quince Therapeutics, Inc.

Quirks, history, and lore behind QNCX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
With no approved products and minimal revenue, it runs on cash reserves and investor faith — the classic biotech burn-rate tightrope walk.
3
The History
The company was rebranded and refocused in the early 2020s, pivoting its pipeline toward rare and serious diseases after shedding its prior identity.
4
The Secret
Its lead program targets Niemann-Pick disease type C, a devastating and ultra-rare lysosomal storage disorder with very few treatment options worldwide.
5
The Lore
The company's drug candidate arimoclomol was acquired and advanced as a potential therapy for a disease so rare it qualifies for orphan drug designation on multiple continents.
6
The Giveaway
Ticker QNCX, named with a nod to the fruit quince — a rare fruit for a company chasing cures for rare diseases, listed on Nasdaq out of San Francisco.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-75.5M

Free Cash Flow

Q2 2026

$-18.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-47.8% YoY

$-84.0MFY 2025

FY22 $-51.7MFY23 $-31.4MFY24 $-56.8MFY25 $-84.0M

Operating Income

-1.4% YoY

$-58.1MFY 2025

FY22 $-52.0MFY23 $-34.6MFY24 $-57.3MFY25 $-58.1M

EPS (Diluted)

-28.2% YoY

$-1.68FY 2025

FY22 $-1.54FY23 $-0.84FY24 $-1.31FY25 $-1.68

Total Assets

-18.3% YoY

$93.5MFY 2025

FY22 $103.9MFY23 $167.9MFY24 $114.5MFY25 $93.5M

Total Debt

+25.9% YoY

$18.0MFY 2025

FY22 $0.00FY23 $13.4MFY24 $14.3MFY25 $18.0M

Op. Cash Flow

-29.8% YoY

$-41.4MFY 2025

FY22 $-44.0MFY23 $-18.3MFY24 $-31.9MFY25 $-41.4M

Free Cash Flow

-29.9% YoY

$-41.8MFY 2025

FY22 $-44.2MFY23 $-18.5MFY24 $-32.2MFY25 $-41.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-84.0M -47.8%	$-56.8M -81.1%	$-31.4M +39.2%	$-51.7M +42.6%	$-89.9M -17.0%	$-76.8M
Operating Income	$-58.1M -1.4%	$-57.3M -65.5%	$-34.6M +33.4%	$-52.0M +42.4%	$-90.3M -14.5%	$-78.9M
EPS (Diluted)	$-1.68 -28.2%	$-1.31 -56.0%	$-0.84 +45.5%	$-1.54 +49.2%	$-3.03	—
Total Assets	$93.5M -18.3%	$114.5M -31.8%	$167.9M +61.6%	$103.9M -22.0%	$133.2M -29.7%	$189.5M
Total Debt	$18.0M +25.9%	$14.3M +6.6%	$13.4M	$0.00	—	—
Operating Cash Flow	$-41.4M -29.8%	$-31.9M -74.4%	$-18.3M +58.5%	$-44.0M +30.0%	$-62.9M -23.8%	$-50.8M
Free Cash Flow	$-41.8M -29.9%	$-32.2M -74.3%	$-18.5M +58.2%	$-44.2M +30.0%	$-63.1M -24.1%	$-50.9M

Get alerted when QNCX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Quince Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of QNCX

BALYASNY ASSET MANAGEMENT L.P.
$12.6M69,967 sh
TUDOR INVESTMENT CORP ET AL
$2.1M117,800 sh
TUDOR INVESTMENT CORP ET AL
$2.1M115,800 sh
Ikarian Capital, LLC
$1.3M72,251 sh
MILLENNIUM MANAGEMENT LLC
$1.3M70,779 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.0M55,000 sh
Squadron Capital Management LLC
$734.4K40,375 sh
GROUP ONE TRADING, L.P.
$351.1K19,300 sh
Shay Capital LLC
$329.3K17,468 sh
BOOTHBAY FUND MANAGEMENT, LLC
$253.0K13,911 sh

Fund	Value	Shares
BALYASNY ASSET MANAGEMENT L.P.	$12.6M	69,967
TUDOR INVESTMENT CORP ET AL	$2.1M	117,800
TUDOR INVESTMENT CORP ET AL	$2.1M	115,800
Ikarian Capital, LLC	$1.3M	72,251
MILLENNIUM MANAGEMENT LLC	$1.3M	70,779
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.0M	55,000
Squadron Capital Management LLC	$734.4K	40,375
GROUP ONE TRADING, L.P.	$351.1K	19,300
Shay Capital LLC	$329.3K	17,468
BOOTHBAY FUND MANAGEMENT, LLC	$253.0K	13,911

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put QNCX on your watchlist

Track score changes the day Quince Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is QNCX a good stock to buy?

13F Pro's AI-powered analysis of Quince Therapeutics, Inc. (QNCX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QNCX are available on the QNCX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. QNCX is classified as a small company.

Which hedge funds own QNCX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QNCX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Quince Therapeutics, Inc.'s investment landscape.